SCHEMBL20889793

SCHEMBL20889793

CC(C)(C)Nc1c(-c2ccc(O)c(O)c2O)nc2cnccn12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SALL4 Q9UJQ4 3/20 0.64
BRD4 O60885 5/20 0.52
TAF1 P21675 1/20 0.52
TAF1L Q8IZX4 1/20 0.52
GAA P10253 9/20 0.50
GFER P55789 3/20 0.50
MAPT P10636 8/20 0.49
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
MAPK1 P28482 3/20 0.49
ALDH1A1 P00352 5/20 0.48
POLB P06746 2/20 0.48
TP53 P04637 4/20 0.47
KDM4E B2RXH2 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
HTT P42858 2/20 0.46
LMNA P02545 2/20 0.46
HSD17B10 Q99714 2/20 0.46
ALOX15 P16050 1/20 0.46
TSHR P16473 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20889790 0.84 SALL4 (0.64) SALL4BRD4MAPTMEN1KMT2A
SCHEMBL20889747 0.80 GAA (0.67) SALL4GAAGFERMAPTMEN1
SCHEMBL20889797 0.78 SALL4 (1.00) SALL4BRD4TAF1TAF1LGAA
SCHEMBL20889692 0.78 SALL4 (0.67) SALL4GAAGFERMAPTMEN1
SCHEMBL31193266 0.78 BRD4 (0.66) SALL4BRD4TAF1TAF1LGAA
SCHEMBL20889689 0.78 GAA (0.71) SALL4GAAGFERMAPTMEN1
SCHEMBL12781599 0.77 ADRA1B (0.71) SALL4BRD4TAF1TAF1LGAA
SCHEMBL20889792 0.77 SALL4 (0.69) SALL4BRD4GAAGFERMAPT
SCHEMBL20889510 0.77 GAA (0.74) SALL4GAAGFERMAPTMEN1
SCHEMBL20889509 0.75 SALL4 (0.68) SALL4GAAGFERMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11530209-B2 Small molecule inhibition of transcription factor SALL4 and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-12-20 US disclosed
US-20200317664-A1 SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2020-10-08 US disclosed
WO-2019070943-A1 SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11530209-B2 Small molecule inhibition of transcription factor SALL4 and uses thereof SALL4, GLI2, TCF4 SALL4 1/4885BRD4 299/4885TAF1 552/4885
US-20200317664-A1 SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF SALL4, GLI2, TCF4 SALL4 1/4885BRD4 299/4885TAF1 552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.